SphK (sphingosine kinase) is the major source of the bioactive lipid and GPCR (G-protein-coupled receptor) agonist S1P (sphingosine 1-phosphate). S1P promotes cell growth, survival and migration, and is a key regulator of lymphocyte trafficking. Inhibition of S1P signalling has been proposed as a strategy for treatment of inflammatory diseases and cancer. In the present paper we describe the discovery and characterization of PF-543, a novel cell-permeant inhibitor of SphK1. PF-543 inhibits SphK1 with a K(i) of 3.6 nM, is sphingosine-competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform. In 1483 head and neck carcinoma cells, which are characterized by high levels of SphK1 expression and an unusually high rate of S1P production, PF-543 decreased the level of endogenous S1P 10-fold with a proportional increase in the level of sphingosine. In contrast with past reports that show that the growth of many cancer cell lines is SphK1-dependent, specific inhibition of SphK1 had no effect on the proliferation and survival of 1483 cells, despite a dramatic change in the cellular S1P/sphingosine ratio. PF-543 was effective as a potent inhibitor of S1P formation in whole blood, indicating that the SphK1 isoform of sphingosine kinase is the major source of S1P in human blood. PF-543 is the most potent inhibitor of SphK1 described to date and it will be useful for dissecting specific roles of SphK1-driven S1P signalling.

No abstract

The aim of this review is to discuss the potential usefulness of a novel class of biochemical markers, neoepitopes, in the context of the US Food and Drug Administration (FDA) Critical Path Initiative, which emphasizes biomarkers of safety and efficacy as areas of pivotal interest. Examples of protein degradation fragments--neoepitopes--that have proven useful for research on bone and cartilage are collagen type I and collagen type II degradation products, respectively. These markers have utility in the translational approach, as they can be used to estimate safety and efficacy in both preclinical models and clinical settings. Biochemical markers of tissue degradation may provide optimal tools, which in combination with other techniques, prove essential to drug discovery and development.

In the present study, capillary liquid chromatography (LC) nano electrospray ionization quadruple time-of-flight (nano-ESI-Q-TOF) mass spectrometry was utilized to identify the unique proteotypic peptides for liquid chromatography-tandem mass spectrometry (LC-MS/MS) mediated breast cancer resistance protein (BCRP/ABCG2) and bile salt export pump (BSEP/ABCG11) quantification, using insect membrane vesicles overexpressing the proteins. The lower limit of quantification was established to be 31.25 pM and 125 nM for BCRP/ABCG2 and BSEP/ABCG11, respectively. The linearity of standard curves was up to 5000 pM. The accuracy and precision of the LC-MS/MS method were evaluated by adding the known amount of synthetic proteotypic peptide or synthetic surrogate peptide substrates in the membrane protein extracts of livers or hepatocytes. The overall relative error (RE) and coefficient of variation (CV) were below 15.9% and 14.2% for BCRP/ABCG2 quantification or below 15.6% and 6.4% for BSEP/ABCG11, respectively. The absolute differences of BCRP/Bcrp and BSEP/Bsep proteins were determined in livers and isolated hepatocytes across species by the newly developed LC-MS/MS methods, with ranking order of dog > rat > monkey approximately = human and rat approximately = monkey > dog approximately = human, respectively (where the uppercase letters identify the human protein, i.e., BSEP and BCRP, and lowercase letters indicate that the transporter derives from a preclinical species, i.e., Bsep and Bcrp). The freshly isolated and cryopreserved hepatocytes conserved the protein levels of BSEP/Bsep and BCRP/Bcrp similarly to those found in liver tissue. We report, for the first time, an absolution quantification method for BCRP/Bcrp and BSEP/Bsep and the differences of the protein expressions across species. The results could serve as supportive information for extrapolation of hepatobiliary elimination from preclinical species to human.

No abstract

The extent of H/D exchange of the protein calmodulin in solution was monitored by mass spectrometry following electrospray ionization (ESI) of the protein. In the absence of Ca2+, approximately 115 protons are exchanged for deuteriums after 60 min. As the calmodulin is titrated with Ca2+, the extent of exchange decreases significantly (i.e., by 24 protons), indicating Ca(2+)-induced folding of the protein to a tighter, less solvent-accessible form. The extent of H/D exchange ceases to decrease when the amount of added Ca2+ is sufficient to convert greater than 80% of the calmodulin to a form bound by four calcium ions. Lysozyme, a protein of similar molecular weight, does not show a significant decrease in the extent of H/D exchange as it binds to Ca2+, indicating that the changes in H/D exchange for calmodulin reflect tertiary structural change that occur upon binding with Ca2+.

Objective. To demonstrate that the novel highly selective matrix metalloproteinase 13 (MMP-13) inhibitor PF152 reduces joint lesions in adult dogs with osteoarthritis (OA) and decreases biomarkers of cartilage degradation.Methods. The potency and selectivity of PF152 were evaluated in vitro using 16 MMPs, TACE, and ADAMTS-4 and ADAMTS-5, as well as ex vivo in human cartilage explants. In vivo effects were evaluated at 3 concentrations in mature beagles with partial medial meniscectomy. Gross and histologic changes in the femorotibial joints were evaluated using various measures of cartilage degeneration. Biomarkers of cartilage turnover were examined in serum, urine, or synovial fluid. Results were analyzed individually and in combination using multivariate analysis.Results. The potent and selective MMP-13 inhibitor PF152 decreased human cartilage degradation ex vivo in a dose-dependent manner. PF152 treatment of dogs with OA reduced cartilage lesions and decreased biomarkers of type II collagen (type II collagen neoepitope) and aggrecan (peptides ending in ARGN or AGEG) degradation. The dose required for significant inhibition varied with the measure used, but multivariate analysis of 6 gross and histologic measures indicated that all doses differed significantly from vehicle but not from each other. Combined analysis of cartilage degradation markers showed similar results.Conclusion. This highly selective MMP-13 inhibitor exhibits chondroprotective effects in mature animals. Biomarkers of cartilage degradation, when evaluated in combination, parallel the joint structural changes induced by the MMP-13 inhibitor. These data support the potential therapeutic value of selective MMP-13 inhibitors and the use of a set of appropriate biomarkers to predict efficacy in OA clinical trials.Osteoarthritis (OA) is a chronic degenerative joint disease affecting primarily aged or injured joints. The disease is characterized by an imbalance between cartilage synthesis and degradation, with increased breakdown of matrix components leading to proteoglycan loss and cartilage fibrillation, eventually resulting in severe cartilage defects. These changes are irreversible, and the only treatment other than palliative symptom control is total joint replacement. Therefore, the discovery of a disease-modifying osteoarthritis drug (DMOAD) would fill a large unmet medical need.

ADAMTS-4 and ADAMTS-Aggrecanase-mediated degradation of aggrecan, the major aggregating proteoglycan of articular cartilage, is an early and sustained feature of osteoarthritis (OA (3, 4). Because of their preference for Glu at P1, both ADAMTS-4 and -5 are considered glutamyl endoproteinases. Whereas ADAMTS-5 is constitutively expressed in human cartilage, ADAMTS-4 is inducible by a number of inflammatory cytokines, such as interleukin-1␤ and tumor necrosis factor-␣ (5). Gene knockout of ADAMTS-5, but not ADAMTS-4, expression in mice has been shown to be chondroprotective in a surgical mouse model of OA (6, 7), yet in human OA cartilage explants both ADAMTS-4 and ADAMTS-5 mediate aggrecan breakdown (8). Inhibition of ADAMTS-4 and ADAMTS-5 activity may represent a viable option for slowing down the progression of cartilage deterioration in OA.Alignment of the known sequences flanking the ADAMTS-4 cleavage sites in the proteoglycan substrates, aggrecan, versican, and brevican, led to the proposal of a 24-amino acid consensus motif (9). Not surprisingly, a glutamic acid residue occupied P1 (100% conserved) with P2Ј occupied by the basic amino acids, Arg or Lys. The authors speculated that activity of ADAMTS family members toward proteoglycan substrates was primarily dictated by an extended 23-amino acid motif N-terminal to the scissile bond, and a short 3-amino acid motif downstream of the site of cleavage. However, unlike the scissile bonds in the aggregating proteoglycans, the site of ADAMTS-4 proteolysis in ␣ 2 -macroglobulin (␣ 2 M) is Met 690 /Gly 691 , with no requirement for Glu at P1 (10). Yet, P1Ј to P3Ј in ␣ 2 M, Gly-Arg-Gly, is remarkably similar to downstream sequences in aggrecan and brevican, implying that PЈ amino acids may be more important in recognition and catalysis than sequences upstream of the scissile bond. ADAMTS-4 has also been shown * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.